Product Description
Mechanisms of Action: PI4K Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Medicines for Malaria Venture
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Malaria, Falciparum|Malaria
Phase 1: Malaria|Malaria, Falciparum
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MMV_MMV390048_17_01 | P1 |
Withdrawn |
Malaria, Falciparum |
2018-09-01 |
|
MMV_MMV390048_16_02 | P2 |
Terminated |
Malaria, Falciparum |
2018-01-01 |
|
MMV_MMV390048_16_01, Part B | P2 |
Completed |
Malaria |
2017-01-16 |
|
MMV_MMV390048_16_01 | P1 |
Completed |
Malaria |
2016-12-01 |